These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 8329109)

  • 41. Clinical feature and anti-phospholipid antibody profiles of pregnancy failure in young women with antiphospholipid antibody syndrome treated with conventional therapy.
    Kaneko K; Mishima S; Goto M; Mitsui M; Tanigaki S; Oku K; Ozawa N; Inoue E; Atsumi T; Sago H; Murashima A
    Mod Rheumatol; 2018 Jul; 28(4):670-675. PubMed ID: 29067844
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phospholipid specificity and requirement of beta 2-glycoprotein-I for reactivity of antibodies from patients with primary antiphospholipid syndrome.
    Cabral AR; Cabiedes J; Alarcón-Segovia D; Sánchez-Guerrero J
    J Autoimmun; 1992 Dec; 5(6):787-801. PubMed ID: 1489489
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study.
    Bouvier S; Cochery-Nouvellon E; Lavigne-Lissalde G; Mercier E; Marchetti T; Balducchi JP; Marès P; Gris JC
    Blood; 2014 Jan; 123(3):404-13. PubMed ID: 24200687
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies.
    Rai RS; Clifford K; Cohen H; Regan L
    Hum Reprod; 1995 Dec; 10(12):3301-4. PubMed ID: 8822463
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes.
    Yelnik CM; Porter TF; Branch DW; Laskin CA; Merrill JT; Guerra MM; Lockshin MD; Buyon JP; Petri M; Sammaritano LR; Stephenson MD; Kim MY; Salmon JE
    Arthritis Rheumatol; 2016 Aug; 68(8):1964-9. PubMed ID: 26990620
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beta 2-glycoprotein I is a good indicator of certain adverse pregnancy conditions.
    Ulcová-Gallová Z; Bouse V; Krizanovská K; Balvín M; Rokyta Z; Netrvalová L
    Int J Fertil Womens Med; 2001; 46(6):304-8. PubMed ID: 11795690
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibodies to phospholipids and nuclear antigens in non-pregnant women with unexplained spontaneous recurrent abortions.
    Bahar AM; Kwak JY; Beer AE; Kim JH; Nelson LA; Beaman KD; Gilman-Sachs A
    J Reprod Immunol; 1993 Aug; 24(3):213-22. PubMed ID: 8229999
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Frequency of antiphospholipid syndrome in women with pregnancy loss in multicenter study in Poland].
    Skrzypczak J; Rajewski M; Wirstlein P; Goździewicz T; Zimmer M; Wołczyński S; Leszczyńska-Gorzelak B; Breborowicz G; Ludwikowski G
    Ginekol Pol; 2011 Oct; 82(10):749-54. PubMed ID: 22379938
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Occasional antiphospholipid antibody positive patients with recurrent pregnancy loss also merit aspirin therapy: a retrospective cohort-control study.
    Sugiura-Ogasawara M; Ozaki Y; Nakanishi T; Sato T; Suzumori N; Kumagai K
    Am J Reprod Immunol; 2008 Mar; 59(3):235-41. PubMed ID: 18275516
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses.
    Sugi T; Katsunuma J; Izumi S; McIntyre JA; Makino T
    Fertil Steril; 1999 Jun; 71(6):1060-5. PubMed ID: 10360910
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association between false-positive TORCH and antiphospholipid antibodies in healthy pregnant women.
    De Carolis S; Tabacco S; Rizzo F; Perrone G; Garufi C; Botta A; Salvi S; Benedetti Panici P; Lanzone A
    Lupus; 2018 Apr; 27(5):841-846. PubMed ID: 29157179
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome.
    Persijn L; Decavele AS; Schouwers S; Devreese K
    Thromb Res; 2011 Dec; 128(6):565-9. PubMed ID: 21529896
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between systemic non-criteria APS manifestations and antibody type and level: results from the Serbian national cohort study.
    Stojanovich L; Kontic M; Djokovic A; Marisavljevic D; Ilijevski N; Stanisavljevic N; Mikovic Z; Petkovic M; Kovcin V
    Clin Exp Rheumatol; 2013; 31(2):234-42. PubMed ID: 23306109
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Laboratory evaluation of anti-phospholipid syndrome: a preliminary prospective study of phosphatidylserine/prothrombin antibodies in an at-risk patient cohort.
    Heikal NM; Jaskowski TD; Malmberg E; Lakos G; Branch DW; Tebo AE
    Clin Exp Immunol; 2015 May; 180(2):218-26. PubMed ID: 25522978
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison between the standard anticardiolipin antibody test and a new phospholipid test in patients with connective tissue diseases.
    Merkel PA; Chang Y; Pierangeli SS; Harris EN; Polisson RP
    J Rheumatol; 1999 Mar; 26(3):591-6. PubMed ID: 10090168
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome.
    Rote NS
    Obstet Gynecol; 1997 Oct; 90(4 Pt 1):642-4. PubMed ID: 9380335
    [No Abstract]   [Full Text] [Related]  

  • 57. Anti-cardiolipin antibodies (IgG and IgA) in women with recurrent fetal loss correlate to clinical and serological characteristics of SLE.
    Bagger PV; Andersen V; Baslund B; Beck B; Hove H; Høier-Madsen M; Petersen J; Philip J; Schaadt O; Skouby SO
    Acta Obstet Gynecol Scand; 1993 Aug; 72(6):465-9. PubMed ID: 8394626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome.
    Andreoli L; Chighizola CB; Nalli C; Gerosa M; Borghi MO; Pregnolato F; Grossi C; Zanola A; Allegri F; Norman GL; Mahler M; Meroni PL; Tincani A
    Arthritis Rheumatol; 2015 May; 67(8):2196-204. PubMed ID: 25939498
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Childhood-onset systemic lupus erythematosus: antiphospholipid antibodies in 37 patients and their first-degree relatives.
    Molta C; Meyer O; Dosquet C; Montes de Oca M; Babron MC; Danon F; Kaplan C; Clémenceau S; Castellano F; Levy M
    Pediatrics; 1993 Dec; 92(6):849-53. PubMed ID: 8233748
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patterns of anti-phospholipid antibody specificities.
    Gilman-Sachs A; Lubinski J; Beer AE; Brend S; Beaman KD
    J Clin Lab Immunol; 1991 Jun; 35(2):83-8. PubMed ID: 1668762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.